Insulin-Like Growth Factor I
Positive response to oral octreotide seen for adults with acromegaly across three trials
BOSTON — The majority of people with acromegaly receiving oral octreotide achieve a biochemical response, regardless of their baseline insulin-like growth factor I level, according to data from a post hoc analysis.
Investigational oral therapy performs similarly to human GH in pediatric GH deficiency
An oral medication that stimulates the growth hormone secretagogue receptor 1a induced height velocity increases similar to those seen with recombinant human GH for children with pediatric GH deficiency, according to trial data.
Once-monthly octreotide provides sustained acromegaly control with fewer injections
BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.
Oral medication lowers IGF-1 levels below upper limit of normal for most with acromegaly
More than half of adults with acromegaly receiving a novel once-daily oral medication achieved an insulin-like growth factor-1 level at or below the upper limit of normal, according to topline results from the PATHFNDR-2 trial.
Thyroid Eye Disease 360˚: A Podcast Series
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Oral acromegaly agent reduces IGF-1 levels below upper limit of normal for most adults
More than 80% of adults with acromegaly achieved an insulin-like growth factor level at or below the upper limit of normal at 36 weeks with an investigational once-daily oral medication, according to topline results from a phase 3 trial.
Growth hormone lowers liver fat for adults with obesity, steatotic liver disease
Adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease had a more than 5% reduction in liver fat at 6 months with growth hormone therapy, according to findings from a randomized controlled trial.
Most adults with acromegaly achieve normal IGF-I levels with long-acting pasireotide
More than half of adults with acromegaly receiving the somatostatin receptor ligand pasireotide achieved normal insulin-like growth factor I levels, according to data from a long-term real-world study.
Women on GH therapy have lower IGF-I levels, experience more adverse effects than men
Women with growth hormone deficiency treated with GH therapy have lower insulin-like growth factor I levels at both baseline and follow-up and experience more adverse events than men, according to study data.
Menopausal hormone changes not linked to loss of strength for aging women
Among postmenopausal women, researchers observed no significant associations between ovarian steroids, adrenal hormones, insulin-like growth factor I, parathormone and vitamin D and handgrip strength, according to study results.